803 patients reached WEGOVY 2.4 mg injection and were then randomized in a 2:1 ratio to either continue on WEGOVY injection or receive placebo
We guide you through medical testing, lifestyle changes, and targeted interventions to prevent rebound weight gain
Many patients also notice improvements in waist circumference and fat distribution within the first 48 weeks
Tirzepatide Semaglutide (Ozempic/Wegovy) activates GLP-1 receptors, which: Slows stomach emptying Reduces appetite Improves insulin sensitivity Typically results in 15-20% weight loss over a year Tirzepatide (Mounjaro/Zepbound) activates both GLP-1 and GIP receptors, which: Provides all semaglutide benefits May have stronger effects on glucose metabolism Often results in 20-25% weight loss over a year Sometimes has fewer gastrointestinal side effects Your optimal choice depends on your specific PCOS presentation
[DOI] [PMC free article] [PubMed] [Google Scholar] 9.Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS
